FDA.reportPublic FDA data

Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]

RxCUI
2665609
RxNorm name
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Display name
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Full name
Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:22

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125761CYFENDUSAnthrax Vaccine Adsorbed, Adjuvanted351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
d4f29180-7c76-40ac-9341-cf62702c4090CYFENDUS 0.1 MG/ML Injectable Suspension [PSN] · Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [Cyfendus] [SBD] · Cyfendus 0.1 MG/ML Injectable Suspension [SY]36These highlights do not include all the information needed to use CYFENDUS safely and effectively. See full prescribing information for CYFENDUS . CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) injectable suspension, for intramuscular use Initial U.S. Approval: 202320260225